Barchas Capital Management sold 211,763 residual shares of Immunome on July 11 [1].
The timing of the sale is significant because it occurred one day before the company's anticipated milestone with the U.S. Food and Drug Administration. Such movements by major shareholders often draw scrutiny regarding the timing of regulatory decisions.
According to filings, the transaction was executed under a Rule 10b5-1 trading plan [1]. This specific regulatory mechanism allows insiders and major investors to sell a predetermined number of shares at a predetermined time to avoid accusations of insider trading. Barchas adopted this specific trading plan in March 2026 [1].
The sale involved residual shares held through both direct and indirect holdings [2]. By utilizing the 10b5-1 plan, the firm established a scheduled exit for these assets months before the current FDA milestone became imminent.
Immunome is currently awaiting a critical decision from the FDA. While the sale of 211,763 shares [1] represents a reduction in Barchas's position, the use of a pre-planned schedule suggests the move was not a reactive response to non-public information regarding the impending regulatory news.
Market analysts typically monitor these filings to gauge investor confidence. In this case, the adherence to a plan created in March 2026 [1] provides a documented timeline that separates the trade from the immediate regulatory window.
“Barchas Capital Management sold 211,763 residual shares of Immunome on July 11”
The use of a Rule 10b5-1 plan is a standard legal safeguard for institutional investors to liquidate positions without triggering insider-trading investigations. Because the plan was adopted in March 2026, the sale on July 11 is technically decoupled from the immediate FDA milestone, signaling that the divestment was a scheduled portfolio adjustment rather than a lack of confidence in the upcoming regulatory outcome.
